The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?

The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04322786

Enrollment

1302508

Registered

2020-03-26

Start date

1998-01-01

Completion date

2021-03-31

Last updated

2020-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom

Brief summary

The study use UK based linked electronic health records from the Clinical Research Datalink (CALIBER) of 5.6 million individuals to conduct a matched case-control study to investigate the incidence of influenza in individuals prescribed ACEI compared to those not prescribed ACEI.

Interventions

DRUGACE inhibitor

Any prescription of ACE inhibitor

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* We identify individuals aged 18 years or older and registered in the current primary care practice for at least one year.

Exclusion criteria

* We exclude individuals with a prior history of influenza and viral pneumonia before study entry.

Design outcomes

Primary

Measure	Time frame
Incidence of influenza	Jan 1st 1998 - May 31st 2016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026